BOLD PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

BOLD ▼ -1.39% at T+20d

SHORT call ✓ call won +1.39% · α vs SPY +1.41% · entry $1.44 → $1.42

Next anchor: T+60d in 8w

Currently $1.40 · +2.78% from $1.44 entry (call sign-flipped)

Entry anchored
May 8, 2026
via day open

T+1d

+7.64%

call -7.64% · α -7.41%

$1.55

settled 4w ago

T+5d

+7.64%

call -7.64% · α -6.18%

$1.55

settled 26d ago

T+20d

-1.39%

call +1.39% · α +1.41%

$1.42

settled yesterday

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Boundless Bio reported Q1 2026 net loss of $13.6M ($0.60/share), wider than the consensus estimate of $0.56 loss per share. The company highlighted ongoing enrollment in its KOMODO-1 trial for BBI-940 and a cash runway of $92.8M into H2 2028, but the EPS miss and lack of revenue (pre-revenue biotech) reinforce the bearish sentiment given the stock's small market cap and high cash burn rate.

Actionable Insight

The EPS miss and continued cash burn without near-term revenue catalysts suggest downside risk. Monitor for KOMODO-1 proof-of-concept data readout, which is the primary value driver. The $92.8M cash runway into H2 2028 provides some buffer but does not offset the lack of fundamental progress.

Key Facts

Net loss of $13.6M for Q1 2026, compared to $15.8M in Q1 2025
EPS of -$0.60 vs consensus -$0.56 (miss of 7.1%)
Cash, cash equivalents, and short-term investments totaled $92.8M as of March 31, 2026
R&D expenses decreased to $9.7M from $12.1M year-over-year
G&A expenses decreased to $4.7M from $5.2M year-over-year
Enrollment ongoing in KOMODO-1 first-in-human trial of BBI-940 for ER+/HER2- breast cancer and TNBC-LAR
Company expects cash to fund operations into second half of 2028

Financial Impact

EPS miss of $0.04 per share (7.1% below consensus) on a net loss of $13.6M; cash burn of ~$14.7M in Q1 2026

epsnet losscash position

Risk Factors

Clinical trial delays or negative data from KOMODO-1 could significantly impair stock value
Cash burn rate of ~$14.7M per quarter implies ~6.3 quarters of runway, potentially requiring dilutive financing before proof-of-concept readout
No approved products or revenue, making the stock highly speculative and binary on trial outcomes

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

0% bullish (7 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3290993

4 reports for BOLD

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for BOLD — sortable, filterable
	Type				Now
May 8, 2026 4w ago	8-K NEUTRAL ★ 3/10	$1.44 $1.42	▼ −1.39%	▼ −1.41%	$1.40 (−2.78%)
May 8, 2026 4w ago	Press Release BEARISH ★ 6/10	$1.44 $1.42	▲ +1.39%	▲ +1.41%	$1.40 (+2.78%)
Apr 17, 2026 7w ago	Press Release BULLISH ★ 7/10	$1.60 $1.42	▼ −11.25%	▼ −15.45%	$1.40 (−12.50%)
Apr 13, 2026 8w ago	8-K BEARISH ★ 7/10	$1.56 $1.55	▲ +0.64%	▲ +6.94%	$1.40 (+10.26%)

US Market Status

Market Closed — Opens Thu (10h 31m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access